The availability of selective S100B biosynthesis inhibitors such as arundic acid is expected to further translational research for neurological and neurodegenerative diseases, and perhaps other disorders, such as inflammatory bowl disease, which are S100B overexpresssion-related. The gene discussed is S100B; the disease is neurodegenerative disease.